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Objective: To develop and validate a uni-dimensional double development high-performance thin layer chromatography (UDDD-HPTLC) for 
estimation of anti-diabetic medicine compromising of metformin (MET) gliclazide (GLZ) and pioglitazone hydrochloride (PIO). 
Methods: The chromatographic separation of these drugs was carried out on precoated TLC plates silica gel 60F254by two mobile phases 
consisting of Ammonium Sulphate: Methanol: Acetonitrile: Water (4:3:2:1) for MET and PIO and Toluene: Ethyl Acetate: Formic Acid (6:4:0.5) for 
GLZ respectively for ideal separation and good resolution. The densitometric detection and quantification were carried out at 237 nm for MET and 
200 nm for GLZ and PIO. The validation parameters were strictly followed as per the ICH guidelines. 
Results: The linearity range was obtained at 3000-8000ng/spot, 360-960 ng/spot, 90-240 ng/spot for MET, GLZ and PIO with r2
Conclusion: In simultaneous estimation, the different polarity of drugs makes it more cumbersome to develop and validate any chromatographic 
method. In the present study, a uni-dimensional double development high-performance thin layer chromatography (UDDD-HPTLC) for estimation 
of these drugs have been developed and validated to resolve the estimation problem. It is an effortless and speedy method which was developed and 
validated using ICH guidelines. The developed and validated method using ICH guidelines is effortless and speedy technique. 
value>0.999. The 
other parameters such as precision, reproducibility, robustness were efficiently obtained within the limits. The proposed method was successfully 
applied for simultaneous determination of MET, GLZ and PIO in the commercial formulation. 
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Metformin (MET) is chemically, 1-carbamimidamido-N-N-dimethyl-
methanimidamide (fig. 1) [1]. It is an oral anti-diabetic drug from the 
biguanide class. It is the first-line drug for the treatment of type-2 
diabetes, particularly in overweight and obese people and those with 
normal kidney function and evidences suggest it may be the best choice 
for the people with heart failure. The major action of MET is increasing 
glucose transport across the cell membrane in skeletal muscle [2]. 
Gliclazide (GLZ) is chemically N-(hexahydrocyclopenta(c) pyrrol-2-
(1H)-ylcarbamoyl)-4-methyl) benzene sulphonamide (fig. 2). 
Gliclazide is an oral hypoglycemic (anti-diabetic) and is classified as 
a sulphonylurea. It is used in type 2 diabetes mellitus that is a non-
insulin dependent diabetes mellitus. GLZ was proven to protect 
human pancreatic beta cells from hyperglycemia-induced apoptosis. 
It was also shown to have an anti-atherogenic effect (preventing the 
accumulation of fat in arteries) in type 2 diabetes. GLZ selectively 
binds to sulphonylurea receptors (SUR-1) on the surface of the 
pancreatic beta-cells [3]. 
Pioglitazone hydrochloride (PIO) is (±)-5-(p-[2-(5-Ethyl-2-pyridyl) 
ethoxy]benzyl)-2,4-thiazolidinedione hydrochloride (fig. 3). 
Pioglitazone belongs thiazolidinedione group which is a class of oral 
anti-diabetic drugs that enhance target tissue insulin sensitivity. 
Pioglitazone has been shown to affect abnormal glucose and lipid 
metabolism associated with insulin resistance by enhancing insulin 
action on peripheral tissues [4]. 
It is observed through a literature review that many 
spectrophotometric and chromatographic methods have been 
reported for the estimation of single as well as combined 
formulations containing Metformin, Gliclazide and Pioglitazone 
hydrochloride [5-15]. 
MET has been simultaneously determined with PIO by 
spectrophotometric methods, [16, 17], by HPLC in the binary 
mixture [18-21], and with other components by HPLC [22-25]. GLZ 
has been simultaneously determined with MET by 
spectrophotometric methods, [26-28], by LC in dosage forms [29-
33], and in human plasma [34, 35]. Spectrophotometric 
determinations have been reported for mixtures composed of more 
than two drugs [36-38]. Literature also reveals the use of the ion-
pairing technique [39-42], and micellar liquid chromatography [43], 
to develop a successful HPLC method for the determination of 
gliclazide and/or metformin. 
Among different analytical tools TLC is one of the multi-applicative, 
quickest, accurate and robust method. However, the literature 
survey does not reveal any HPTLC method for simultaneous 
estimation of MET, GLZ and PIO in combined tablet dosage form. The 
reason for this can be the polarity difference among the three drugs. 
But, TLC application is so diverse that it offers various special 
development modes such, as multidimensional development, uni-
dimensional multiple development (UMD), incremental multiple 
development (IMD), gradient multiple development (GMD), etc. [44]. 
All these methods, improve the resolution of the components 
because of each consecutive development results in band re-
concentration and thus, it enhances the efficiency of the separation 
[44, 45]. In this current research work, we have applied the same 
principle and have successfully developed and validate UDDD-
HPTLC method for the simultaneous estimation of MET, GLZ and 
PIO.  
Therefore, a simple and new UDDD-HPTLC method has been 
developed and validated for their estimation of MET, GLZ and PIO in 
bulk and combined tablet dosage form. UDDD-HPTLC techniques 
allow separation of compounds with a large difference in polarity. 
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When the combined formulation have drugs with different polarity 
the chromatographic study like HPLC becomes costly, tedious and 
more time-consuming affair. Thus, in such case, HPTLC method with 
robust, easy detection and time-saving characteristics can be 
effectively employed.  
 
 
Fig. 1: Structure of metformin (MET) 
 
 
Fig. 2: Structure of gliclazide (GLZ) 
 
 
Fig. 3: Structure of pioglitazone hydrochloride (PIO) 
 
MATERIALS AND METHODS 
Chemical and reagents 
MET, GLZ and PIO API procured as a gift sample from Ipca 
Laboratories Limited Mumbai. The marketed formulation 
(Glycinorm Total) with fixed dose combination tablets of the three 
compounds, (MET, GLZ, PIO) was purchased from retail pharmacy in 
Mumbai (Maharashtra, India). Other chemicals and reagents of 
analytical grade were purchased from Merck (India). 
Chromatographic conditions 
A CAMAG HPTLC system equipped with Linomat 5 autosampler, TLC 
scanner 3, and winCATS 1.2.2 software (CAMAG, Muttens, 
Switzerland) was employed. The slit dimension was kept at 5.00 × 
0.45 mm, and 20 mm/sec scanning speed was employed. 
Chromatography was performed on precoated silica gel 60 F254 TLC 
plates (20 × 10 cm,) (Merck, Darmstadt, Germany) using Ammonium 
Sulphate: Methanol: Acetonitrile: Water (4:3:2:1) for MET and PIO 
and Toluene: Ethyl Acetate: Formic Acid (6:4:0.5) for GLZ 
respectively as mobile phase. The band length 6 mm and distance 
between bands 15 mm were kept constant throughout the study. 
The application speed was 150 nl/sec. Ascending development to a 
distance of 85 mm was performed on 20×10 cm twin through the 
chamber (CAMAG). Densitometric scanning was achieved over a 
camag TLC scanner III operated using winCATS software (V 1.4.4. 
CAMAG). The source of radiation used was a UV Spectrophotometer, 
using spectral data the λmax was determined for each compound. 
Preparation of solutions 
Standard stock solution 
The standard stock solutions with a concentration of 1 mg/ml of the 
individual standard were prepared in methanol. 
Sample stock solution 
Twenty tablets were weighed and crushed to a fine powder. The 
quantity of powder equivalent to 500 mg MET, 60 mg GLZ and 15 mg 
PIO was weighed and transferred to a 100 ml volumetric flask. The 
solution containing 5 mg/ml MET and 0.6 mg/ml GLZ 0.15 mg/ml 
PIO. The solution was filtered through Whatmann filter paper 
number 41.  
Validation of the method 
Linearity  
The standard stock solution with 1 mg/ml each MET and GLZ, PIO 
were prepared in methanol. Different volumes of each solution were 
applied to the HPTLC plate to deliver 3000-8000 ng of MET, 360-960 
ng of GLZ, 90-240 ng of PIO per spot. Each concentration was 
analyzed in duplicate [46]. 
Precision 
The precision of the developed method was evaluated by performing 
intra-day and inter-day precision. Intra-day precision was assessed 
based on triplicate of three different concentrations of MET (3000, 
5000, 7000ng/spot), GLZ (360,600,960ng/spot) and PIO 
(90,150,240 ng/spot). The inter-day precision of the method was 
verified by performing a similar method on different days under the 
same set of experimental conditions. The repeatability study of the 
same application and calculation of the peak area for the analyte was 
articulated in terms of the % RSD [46].  
Accuracy 
The accuracy of the method was assessed by determination of 
recovery of the method at 3 different concentrations (80%, 100% 
and 120% levels) by addition of known amounts of MET, GLZ and 
PIO. At each level, six determinations were performed to evaluate 
the accuracy studies. The results were recorded in the form of 
percent recovery and percent RSD of all three drugs [46]. 
Limit of detection and limit of quantitation 
The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample that can be detected but not 
necessarily quantitated as an exact value. The quantitation limit of 
an individual analytical procedure is the lowest amount of analyte in 
a sample that can be quantitatively determined with suitable 
precision and accuracy. In order to estimate the limit of detection 
(LOD) and limit of quantitation (LOQ), the signal to noise ratio (S/N) 
of 3 and 10 was determined for six to replicate determinations for 
each drug [46]. 
Specificity 
The specificity of the method was by means of complete separation 
of pure drugs in the presence of other excipients normally present in 
the formulation. Peak purity of MET, GLZ and PIO was assessed by 
comparing their respective spectra at peak start (S), peak apex (M) 
and peak end (E) position of the spots [46].  
Robustness 
The robustness was studied by evaluating the effect of small but 
deliberate variations in the chromatographic conditions. Following 
the introduction of small changes in the mobile phase composition 
(±0.1 ml for each component), the amount of mobile phase was 
varied over the range of±5%. The time from spotting to 
chromatography and from chromatography to scanning was varied 
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by+10 min. The effect of these changes on both the Rf values and 
peak areas was examined by calculating the %RSD for each 
parameter [46]. 
Analysis of tablet sample  
The validated method was used for the simultaneous quantitation of 
Metformin, Gliclazide and Pioglitazone hydrochloride in the tablet 
dosage form. Further, 5 ml of stock solution of the sample was diluted 
with 10 ml of methanol to get the concentration of 2.5 mg/ml MET, 0.3 
mg/ml GLZ and 0.75 mg/ml PIO. The analysis was repeated in 
triplicate [46].  
RESULTS AND DISCUSSION  
Chromatographic separation of the standard solution of MET, GLZ 
and was performed. Briefly, the spot of the standard solution was 
applied on TLC plates. The TLC plates were developed by linear 
ascending development by using various solvents such as acetone, 
benzene, chloroform, ethyl acetate, methanol and toluene. The 
experimental condition for the HPTLC method such as mobile phase 
composition and the wavelength of detection was optimized to 
provide accurate, precise and reproducible, compact, flat bands for 
simultaneous determination of MET, GLZ and PIO. 
During the stage of method development different mobile phases 
were tried and the mobile phase comprising of Ammonium 
Sulphate: Methanol: Acetonitrile: Water (4:3:2:1) for MET and PIO 
and Toluene: Ethyl Acetate: Formic Acid (6:4:0.5) for GLZ 
respectively were confirmed. The spectral data revealed the λ max 
for MET at 237 nm and for GLZ and PIO at 200 nm. The 
chromatographic conditions confirmed for the analysis gave well-
resolved peaks for each standard. (fig. 4 and fig. 5). 
A good linear relationship was obtained over the concentration ranges 
200-1000, 360-960 and 90-240 ng/spot for MET, GLZ and PIO 
respectively. The linear regression data showed a regression 
coefficient of 0.9993 for MET (fig. 6), 0.9987 for GlZ (fig. 7) and 0.9993 
for PIO (fig. 8). The LOD with signal/noise ratio was found to be 357.7, 
150.24 and 61.745 ng/spot for MET, GLZ, and PIO respectively. The 
LOQ with signal/noise ratio was found to be 1084.0, 455.27 and 
187.105 ng/spot for MET, GLZ, and PIO respectively.
 
 
Fig. 4: HPTLC profile of MET and PIO 
 
 
Fig. 5: HPTLC profile of GLZ 
 
The intraday and inter-day precision showed excellent % RSD less 
than 2 % (table 1, 2 and 3). The recovery was 101.6, 101.4 and 
100.6% for MET, 99.8, 100.4 and 100.6 % for GLZ and 100.6, 99.1, 
101.7 % for PIO at 80%, 100% and 120% levels (table 4). The 
robustness parameter was also successfully carried and the results 
were satisfying and within the limits. (table 5.1, 5.2, 5.3)
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Fig. 6: Linearity graph of MET 
 
 
Fig. 6: Linearity graph of GLZ 
 
 
Fig. 6: Linearity graph of PIO 
 
Table 1: Evaluation of intra-day and inter-day precision of MET 
MET taken (ng/spot) Intra-day precision Inter-day precision 
MET found(ng/spot) mean±SD % RSD MET found (ng/spot) mean±SD % RSD 
3000 3080.4±50.52 1.64 3037.8±26.13 0.86 
5000 5134.8±91.91 1.79 5220.7±81.96 1.57 
7000 7119.7±128.87 1.81 7356.3±100.78 1.37 
SD=Standard deviation, RSD= relative standard deviation  
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Table 2: Evaluation of intra-day and inter-day precision of GLZ 
GLZ taken (ng/spot) Intra-day precision Inter-day precision 
GLZ found(ng/spot) mean±SD % RSD GLZ found (ng/spot) mean±SD % RSD 
360 357.3±4.93 1.38 355.6±3.13 0.88 
600 598.6±6.46 1.08 597.1±5.37 0.90 
960 969.4±13.77 1.42 965.6±15.16 1.57 
SD=Standard deviation, RSD= Relative Standard deviation 
 
Table 3: Evaluation of intra-day and inter-day precision of PIO 
PIO taken (ng/spot) Intra-day precision Inter-day precision 
PIO found (ng/spot) mean±SD % RSD PIO found (ng/spot) mean±SD % RSD 
90 97.6±1.82 1.86 97.3±170.28 1.75 
150 149.7±2.77 1.85 150.0±1.38 0.92 
240 235.4±4.26 1.81 234.8±3.38 1.44 
SD=Standard deviation, RSD= Relative Standard deviation 
 
Table 4: Recovery data of MET, GLZ and PIO 
Level (%) Amount added (ng) Amount found (ng) mean±SD % Recovery 
MET GLZ PIO MET GLZ PIO MET GLZ PIO 
80 4800 580 150 4868±16.99 582±10.23 149±1.29 101.4 100.4 99.1 
100 6000 720 180 6094±41.63  718±5.06 181±2.39 101.6 99.8 100.6 
120 7200 860 220 7245±84.02 865±12.65 224±1.15 100.4 100.6 101.7 
SD=Standard deviation, RSD= Relative Standard deviation 
 
Table 5.1: Robustness study for developed study of metformin 
Parameter MET  
Concentration in ng/spot 3000 5000 7000 %RSD 
Mobile phase composition (±0.1 ml) mean±SD 6425.33±99.51  10425.33±100.50 14300.33±77.72 1.02 
Amount of mobile phase (±5%) mean±SD 6315±95.69  10319.3±73.42  14342.7±167.73  1.13 
Time from spotting to chromatography (±10 min) mean±SD 6328±72.08  10526.33±204.26  14461.67±204.26  1.63 
Time from chromatography to scanning (±10 min) mean±SD 6863.67±115.94  10718.33±170.10  14692.67±159.10  1.45 
SD=Standard deviation, RSD= Relative Standard deviation 
 
Table 5.2: Robustness study for developed study of Gliclazide 
Parameter GLZ  
Concentration in ng/spot 360 600 960 %RSD 
Mobile phase composition (±0.1 ml) mean±SD 1878.67±16.50 3085.33±36.64 4759.33±85.01 1.28 
Amount of mobile phase (±5%) mean±SD 1845.67±23.01 3083.00±35.79 4937.67±35.10 1.04 
Time from spotting to chromatography (±10 min) mean±SD 1855.33±12.34 3079.67±41.05 4892.3±14.2 0.76 
Time from chromatography to scanning (±10 min) mean±SD 1848.00±3.61 3045.67±45.65 4881.33±62.07 0.99 
SD=Standard deviation, RSD= Relative Standard deviation 
 
Table 5.3: Robustness study for developed study of Pioglitazone hydrochloride 
Parameter PIO  
Concentration in ng/spot 90 150 240 %RSD 
Mobile phase composition (±0.1 ml) mean±SD 1126.67±14.503 1725.67±3.512 2741.33±25.813 0.81 
Amount of mobile phase (±5%) mean±SD 1129±14.526 1747±28.919 2739±36.497 1.42 
Time from spotting to chromatography (±10 min) mean±SD 1117.67±4.163 1729±11.14 2706.33±77.37 1.29 
Time from chromatography to scanning (±10 min) mean±SD 1116.33±7.51 1735.33±15.31 2717±37.47 0.98 
SD=Standard deviation, RSD= Relative Standard deviation 
 
This developed and validated the method for the simultaneous analysis 
of MET, GLZ and PIO in pharmaceutical preparations was successfully 
employed. The assay results of tablet dosage form are shown in table 6. 
Assay results show excellent label claim of 99.4% for Metformin, 100.1% 
for Gliclazide and 99.7 % for Pioglitazone hydrochloride. Final, optimum 
characteristics and validation parameters are summarized in table 7.
 
Table 6: Assay results of tablet dosage form 
Formulation Actual added (mg) Amount found±(mg) % drug found±SD 
Glycinorm Total MET GLZ PIO MET GLZ PIO MET GLZ PIO 
500 60 15 498 58.8 14.2 99.4±0.15 100.1±0.09 99.7±0.08 
SD=Standard deviation, RSD= Relative Standard deviation 
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Table 7: Optical characteristic and validation parameter of MET, GLZ and PIO 
 Parameter MET GLZ PIO 
Wavelength 237 200 200 
Linearity range (ng/Spot)  3000-8000 360-960 90-240 
Correlation co-efficient (r2) mean±SD 0.9993±0.0019 0.9987±0.0006 0.9993±0.0012 
Retention factor  0.22 0.60 0.48 
Intercept  94.43 39.92 31.39 
Slope of regression 2.00 5.03 11.43 
Limit of detection (LOD, ng/spot)  179.06 29.59 5.40 
Limit of quantitation (LOQ, ng/spot)  542.61 89.65 13.60 
Assay (%) mean±SD 99.4±0.15 100.1±0.09 99.7±0.08 
SD=Standard deviation, RSD= Relative Standard deviation 
 
CONCLUSION 
The developed UDDD-HPTLC method is new, less time consuming, 
precise, accurate and robust. The double development feature in TLC 
method enables estimation of any kind of compounds simultaneously. 
It is concluded that the developed method offers several advantages 
such as rapid, cost-effective, simple mobile phase, easy sample 
preparation steps and improved sensitivity made it reliable and easily 
reproducible in quality control set-up providing all the parameters are 
followed accurately for its intended use. The proposed UDDD-HPTLC 
method is novel, less expensive, simpler, rapid, and more flexible than 
HPLC. This method allows simultaneous estimation of all API on one 
single TLC plate with a single application and thus, it can be employed 
for routine quality control analysis. 
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